000463: PRIMARY AND METASTATIC OVARIAN CANCER IN PATIENTS WITH PRIOR BREAST CARCINOMA. PREOPERATIVE MARKERS AND TREATMENT RESULTS

Aim and Material: The goal was to retrospectively analyze the characteristics of women with prior breast cancer, that were operated either for primary or metastatic cancer, between 1987-2003, in order to identify preoperative markers useful in the differential diagnosis. Results: Twenty seven patients were diagnosed with primary epithelial ovarian cancer (POC), and 9 had metastatic disease (MOC) (3:1). The median interval between breast-ovarian cancer was 8 years. CA 125 was elevated in 70% of POC group and in 56% of MOC, but the median level was higher. Ca 15-3 > 100 i/ml was in 89% of M.O.C group (p = 0,0002). BrCA mutation risk, (BRCAPRO software program), was 41,8% and 9% in POC and MOC respectively (p = 0,0477). Ovarian spread was not the only site of metastatic breast cancer in 55,5% of MOC group, compared to 11% of POC. 78% of patients had unilateral tumors in the POC group and bilateral in the MOC (p = 0,0133). Optimal Cytoreduction was feasible in 67% of POC and 44% of MOC. Median survival was 10 months for MOC and 33 months for POC (p